title: [Long-acting injectable antipsychotics. Overview and advice for daily routine care].
abstract: Recent investigations have demonstrated a significant reduction of relapse and hospitalization rates associated with the use of long-acting injectable antipsychotics (LAIs) in the treatment of schizophrenia. There are only marginal differences in the effectiveness of different specific LAIs. Furthermore, LAIs are comparable to the oral equivalents with respect to effectiveness and side effects. The occurrence of extrapyramidal motor disorders (EPD) is less frequent in second generation (SG) LAIs than in first generation (FG) LAIs. Moreover, specific characteristics of some substances should be considered: In SG-LAIs immediate onset of action is only applicable for olanzapine and paliperidone and FG-LAIs should always be given as a test dose first to assure a general tolerance. All LAIs have a high variability of plasma levels which complicates the dose titration. Last but not least, current research concerning long-term consequences of continuous treatment with antipsychotics and the potentially poorer response to antipsychotics should be considered.
authors.affiliation: Klinik für Psychiatrie und Psychotherapie, Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Deutschland, stephan.koehler@charite.de.
authors.forename: S
authors.initials: S
authors.lastname: Köhler
authors.forename: A
authors.initials: A
authors.lastname: Heinz
authors.forename: P
authors.initials: P
authors.lastname: Sterzer
mesh_terms: D000465:Algorithms; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000145:classification*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007275:Injections, Intravenous; D012559:Schizophrenia / Q000188:drug therapy* / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations